A chemical called cysteamine has long been of interest as a potential therapy for Huntington’s disease. Now, Raptor Pharmaceuticals has announced the interim results of a study of cysteamine in HD patients. The trial failed to meet its pre-specified goal, but there are some interesting details in …
